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Objective: the aim of this study was to investigate the effect of currently recommended medical treatment (MT) on changes
in carotid stenosis in a group of asymptomatic patients taken from the Asymptomatic Carotid Surgery Trial (ACST).
Method: collaborators in ACST were given information on MT for stroke prevention (including antiplatelet agents, lipid-
lowering drugs, diabetic and hypertension control). Patients underwent clinical examination and duplex scanning at entry,
4 months following randomisation and annually thereafter. The cohort of patients studied were those randomised to MT
with complete follow up duplex datasets at four years (n 219). None had undergone carotid endarterectomy (CEA) or
developed ipsilateral carotid symptoms.
Results: there was no change in median carotid stenosis over four years (baseline 79% (IQR 10%) and 4 year median 79%
(IQR 10%)) a median difference of 0 with Q1 ÿ5 and Q35 (p 0.98 Wilcoxon one sample test), whilst in many
patients' stenoses progressed and regressed during this time. No individual MT variable correlated with stenosis progres-
sion or regression.
Conclusion: in this group of ACST patients on MT, mean carotid stenosis was unchanged over 4 years. Individual
patients' stenoses progressed (and regressed) without symptoms occurring. An increase in stenosis should not be the sole
basis for deciding to operate on an asymptomatic patient.
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The purpose of this study was to investigate carotid
stenosis changes in patients from the ongoing Asymp-
tomatic Carotid Surgery Trial (ACST). The natural
history of carotid stenosis is very important, as sever-
ity of stenosis and stenosis progression are thought
to be predictors of stroke risk.1±4 Recent studies
have demonstrated that aggressive use of statins can
slow and regress carotid intima media thickness, but
these studies have been conducted in patients with
very early atherosclerosis.5,6 The effect of currently
recommended Medical Treatment (MT) in patients
with moderate or advanced carotid stenosis is unclear.
This study sought to investigate this in a group of
patients who remained asymptomatic and who had
been followed up for 4 years.This paper was presented at the ESVS 2001 in Lucerne, Switzerland.
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Patients were recruited into ACST if they were found
to have an asymptomatic carotid stenosis, which might
be suitable for carotid endarterectomy (CEA). Asymp-
tomatic was defined as not having suffered from ipsi-
lateral transient ischaemic attack (TIA), amaurosis
fugax or stroke within the previous 6 months. After
patients consented, they were randomised in equal
numbers to either CEA and MTor MTalone.
At study entry vascular risk factors were assessed
(blood pressure, total cholesterol level and diabetic
status) and patients underwent neurological examin-
ation. Established coronary artery disease was
assessed by history. Medication was noted by group
(i.e. antihypertensive, antiplatelet, anticoagulants
and lipid-lowering therapy). A history of previous
(greater than 6 months) ipsilateral symptoms or
brain scan evidence of cerebral infarction were
noted. On entry current carotid stenosis was assessed
by duplex scanning.
ACST subjects were followed up 4 months after
entry and annually thereafter. At each follow-up theyll rights reserved.
Table 1.
Baseline characteristics (n 219)
Male/female 151/68
Mean age (years) 68
No. of diabetics 51 (23%)
Mean cholesterol (mmol/l) 6.0 (IQR 5.3±6.8)
Mean systolic blood pressure (mmHg) 155 (IQR 140±170)
Mean diastolic blood pressure (mmHg) 83 (IQR 80±90)
520 S. P. Sleight et al.underwent duplex scanning and had their blood
pressure measured. Current drug therapy was noted.
History and examination were performed to assess
for symptoms (stroke, TIA).
The aim of the present study was to assess change
in carotid stenosis and the effect of MT on patients
randomised to this arm of the study. In this paper,
the ACST database was interrogated; only patients
with complete duplex data sets for four years were
included and only the carotid artery that had been
considered for surgery was studied. Patients were
excluded if they had any data missing, had a major
event (death, stroke) or had carotid intervention dur-
ing follow up.
Medical therapy (MT)
Centres participating in ACST were sent the trial
protocol7 which included guidelines for appropriate
MT. These consisted of optimal and rigorous control
of blood pressure (hypertension requiring treatment
was defined as greater than 160/90 mmHg) and
diabetes, advice regarding cessation of smoking
and either antiplatelet or anticoagulation treatment.
Cholesterol lowering was advised if total cholesterol
was greater than five mmol/l at baseline. Ischaemic
heart disease whether symptomatic or uncovered by
investigation should have been appropriately treated
and was not a reason for exclusion from ACST (how-
ever simultaneous CEA and coronary artery bypass
was not allowed).
Duplex scanning
At each follow-up, patients underwent further duplex
scanning. Median carotid stenosis of the group was
studied over time. Centres used their preferred scan-
ning technique to calculate stenosis in keeping with
the study protocol. Estimation of stenosis had to be
expressed as percentage diameter reduction but no
specified duplex scanning method was imposed on
centres. We analysed actual reported change over
the four year period (four year value minus baseline
stenosis) and divided them into 10% categories.
However in keeping with recent studies and for com-
parative purposes, we undertook a separate analysis
using Strandness' criteria. Strandness categorised
diameter reduction and stenoses into group (0%,
1±14%, 15±49%, 50±79%, 80±99%) using duplex ultra-
sound.1,8 Progression, in this study was then defined
as advancement to a higher category at any time
during follow up. In patients who had progressed toEur J Vasc Endovasc Surg Vol 23, June 2002a higher category we also recorded those who subse-
quently returned to the lower level.
Regression was similarly defined as a change to
a lower category at 4 years compared to baseline
value.
Statistical Methods and Analysis
Spearman's non-parametric correlation coefficients
were calculated. One- and two-sample Wilcoxon and
the Chi-squared tests were used to study gender,
baseline cholesterol, patients on lipid-lowering treat-
ment at baseline and four years, baseline blood pres-
sure and change in blood pressure between baseline
and four years. Median values and interquartile
ranges were calculated. The tests were two sided and
p5 0.05 was considered significant.
Results
Currently there are 1386 patients in the MT arm of
ACST, and 853 have been followed up for four
years. Two hundred and nineteen (16%) MT
patients fulfilled all the entry criteria for this study
(all 6 duplex scans reported and no major event or
operation) representing 49 centres and 15 countries.
The mean age of the group was 68 years. The mean
cholesterol level at baseline was 6.0 mmol/l and
23% (51/219) were diabetic (see Table 1).
The median percentage carotid stenosis was plotted
against time (Fig. 1). There was no change over the
four years (baseline 79% (IQR 10%) and 4 year
median 79% (IQR 10%), a median difference of 0%
Q1ÿ5, Q35, p 0.98 one-sample Wilcoxon
test). The change in percentage stenosis (in 10% incre-
ments) of individuals was analysed from baseline to 4
years (Fig. 2). There was no association between indi-
vidual absolute change in stenosis and gender (p 0.9
Chi-squared), baseline cholesterol or blood pressure
(p 0.3±0.8 two-sample Wilcoxon test). There was
also no correlation between change in either blood
Fig. 1. Median carotid stenosis and the interquartile range of 219 patients randomised to currently recommended Medical Treatment
followed for 4 years. There was no change in median carotid stenosis over 4 years (baseline 79% (IQR 10%)) and 4 year median 79% (IQR
10%), a median difference of 0 with Q1ÿ5 and Q35 (p 0.98 Wilcoxon one-sample test).
Fig. 2. Changes in individual carotid stenosis from baseline to
4 years (ÿvalues represent regression and  values represent pro-
gression in stenosis) grouped by 10% categories.
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4 years (p 0.25 Spearman), nor was there an associ-
ation between stenosis change and whether patients
were taking lipid-lowering treatment (p 0.9 two-
sample Wilcoxon test).
Patients' stenoses were also classified by Strand-
ness' criteria: 15±49%: (n 2), 50±79%: (n 110),
80±99%: (n 107). When comparing only the baseline
and 4 year stenosis values; 31 patients regressed to
a lower group, 148 patients remained in the same
group, 37 patients progressed by one group and 3
by two categories. However by defining progression
as an increase of stenosis to a higher category at
any time during follow-up, 51 patients progressed
(123 patients remained in the same group and45 patients regressed). Ten of the 51 who progressed
subsequently `` regressed'' to their original category at
a later follow-up.
Those patients whose stenosis progressed at any
stage to a higher category (by Strandness' criteria)
were compared with the rest. There were no signifi-
cant differences by gender, baseline cholesterol,
blood pressure (and change in mean blood pressure)
and lipid-lowering treatment between those who
progressed (n 51) and those who did not (n 168)
(p values4 0.5).
Discussion
This study analysed changes in carotid stenosis in
a group of patients from the ACST randomised to
MT. None of these had major events and none had
CEA. Patients who were symptomatic had been
excluded as ACST is still ongoing and the current
findings are blinded to all except the data monitoring
committee. This group represents those patients who
have been followed for four years and who fulfilled
the inclusion/exclusion criteria; none were speci-
fically or individually selected. Many of those fol-
lowed for four years were excluded because of
incomplete duplex reporting. This is because whilst
overall follow up is excellent, many centres do not
have the resources to perform annual duplex scan-
ning. However when those patients with incompleteEur J Vasc Endovasc Surg Vol 23, June 2002
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there was still no change in carotid stenosis over
4 years.
The results in this selected group demonstrate that
mean carotid stenosis did not change over 4 years.
This may be surprising, as some might expect to
see overall progression in a group such as this who
have moderate to severe carotid stenosis,8 even
though we have excluded those who were symptom-
atic. It is also difficult to attribute this result to
individual components of the MT as none of the ana-
lyses performed demonstrated differences between
patients who progressed and those that did not.
Other studies have grouped stenoses by Strandness'
criteria and defined progression by advancement
into a higher group.8,9 In ACST many centres do not
use this method and therefore it may be inappropriate
to categorise the data by these criteria. To compare
with other studies this analysis was performed and
none of the specific variables were associated with
progression or regression.
Muluk et al. studied the natural history of carotid
stenosis in a large number of patients; the majority
of whom had negligible or only very mild stenosis
at the beginning of the study.8 They demonstrated
that a systolic blood pressure of greater than
160 mmHg at baseline was associated with a greater
risk of progression of carotid stenosis. Our study did
not confirm this even though our patients had tighter
carotid stenosis.
McMahon, in the LIPID study of 552 patients with
early (non-stenotic) atherosclerosis demonstrated
that 4 years of pravastatin therapy resulted in a
decrease in carotid wall thickness.5 Smilde demon-
strated a similar regression in carotid intima media
thickness in patients with (non-stenotic) early athero-
sclerosis with familial hypercholesterolaemia who
were treated with aggressive atorvastatin therapy for
2 years.6 However, Liapis studied patients with
mild stenosis (mean stenosis 45%) and found that
hypercholesterolaemia did not correlate with
stenosis progression.10 The findings from our study
are similar.
There is no standardised technique of duplex scan-
ning, but because ACST is very large, individual
centres' variations are less important. Furthermore
the individual patient is followed at the same
centre each visit and centres are asked to validate
their own techniques. By not imposing a standard
technique, the patients entered represent normal
day to day practice of the trial collaborators, and re-
flect the stenosis values on which their decisions
are based. Recently a study has been performed in
patients from ACST centres that perform angiographyEur J Vasc Endovasc Surg Vol 23, June 2002and duplex ultrasound; this showed good correlation
between angiography and duplex ultrasound in
one hundred patients (unpublished).
The use of x-ray contrast angiography is becoming
more selective with many centres now relying on du-
plex ultrasound alone or in conjunction with magnetic
resonance imaging. All methods of assessment have
scope for error whether overestimating or underesti-
mating stenosis values. All clinicians will have
encountered these difficulties when following up
patients who are asymptomatic with significant ca-
rotid stenoses especially as stenosis progression and
severe baseline stenosis are thought to be associated
with subsequent neurological events.1±4
The only reported large trial supporting pro-
phylactic CEA for asymptomatic carotid stenosis is
the Asymptomatic Carotid Atherosclerosis Study
(ACAS). ACAS demonstrated that patients who had
an asymptomatic carotid stenosis of greater than
60% (measured by angiography) did better with CEA
than conservative treatment in preventing stroke.11
Since ACAS was published in 1995 there has been a
large increase in the number of prophylactic CEAs
performed.12 However ACAS failed to demonstrate
any increased benefit in operating on patients with
very tight (80±99%) stenosis, when compared with
the overall group. Despite this, others have advised
patients with duplex Doppler ultrasound stenoses of
greater than 70% that are asymptomatic to undergo
CEA.8,10 The results of our study have highlighted
the difficulty of relying on the value of `` actual'' sten-
osis to decide on when to operate on aysmptomatic
patients. If decisions are made purely on the basis of
`progression' then many patients would have under-
gone CEA even though they remained asymptomatic
and some if left would have `` regressed'' by the fol-
lowing visit. The mortality and morbidity from CEA
in asymptomatic patients is significant and probably
much higher than the very low rate of morbidity and
mortality found in ACAS (less than 3%). Rothwell,
Wong and Kucey separately investigated outcomes
of carotid endarterectomy for asymptomatic carotid
stenosis and found overall combined stroke and
death rates varied from 3.35±5.1%.13±15 These results
may mean that there is no benefit in prophylactic
CEA; at present many believe surgery is not cost ef-
fective and that much stronger evidence of stroke
prevention is needed.
The only ongoing trial, which should help to
answer these questions is the ACST. After analysis
and, if appropriate metanalysis, it should be possible
to determine whether operation is justified for
patients with asymptomatic carotid stenosis. This
study demonstrates that appropriate MT, without
Treatment of Asymptomatic Carotid Stenosis 523operation, is not associated with increasing carotid
stenosis in this group of otherwise asymptomatic
patients.
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